Evidence map›Paper›PMID 36265483›Full record

ArticleCell reports. Medicine2022

Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study.

Jiao Hu, Jinbo Chen, Zhenyu Ou, Haige Chen, Zheng Liu, Minfeng Chen, Ruiyun Zhang, Anze Yu, Rui Cao, Enchong Zhang and 20 more

Registry-linked trialOpen access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06727214 (Survival Benefit of Neoadjuvant Systemic Chemotherapy in Muscle Invasive Bladder Cancer and Factors Affecting Its Response - Retrospective Study), which is not on this map. Cited by 87 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 6 pooled it
31.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06727214 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Survival Benefit of Neoadjuvant Systemic Chemotherapy in Muscle Invasive Bladder Cancer and Factors Affecting Its Response - Retrospective Study

TypeobservationalSponsorSara Mahmoud Ahmed MahmoudRan2025 to 2026Enrolled87ConditionsBladder Urothelial CarcinomaArmsChemotherapy with platine
3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 6 syntheses or guidelines pooled it, 136 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 11 institutions in 1 country.

Jiao HuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Jinbo ChenDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Zhenyu OuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Haige ChenDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Zheng LiuDepartment of Urology, Tongji Hospital, Huazhong University of Science & Technology, Wuhan, China.
Minfeng ChenDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Ruiyun ZhangDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Anze YuDepartment of Urology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Rui CaoDepartment of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Enchong ZhangDepartment of Urology, Shengjing Hospital, China Medical University, Shenyang, China.
Xi GuoDepartment of Urology, Hunan Provincial People's Hospital, the First Affiliated Hospital of Hunan Normal University, Changsha, China.
Bo PengDepartment of Urology, Zhangjiajie People's Hospital, Zhangjiajie, China.
Dingshan DengDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Chunliang ChengDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Jinhui LiuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Huihuang LiDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Yihua ZouDepartment of Urology, the First People's Hospital of Chenzhou, Chenzhou, China.
Ruoping DengDepartment of Urology, the Central Hospital of Yongzhou, Yongzhou, China.
Gang QinDepartment of Urology, the Central Hospital of Yongzhou, Yongzhou, China.
Wenze LiDepartment of Urology, the First People's Hospital of Xiangtan City, Xiangtan, China.
Lue WangDepartment of Urology, Huarong People's Hospital, Yueyang, China.
Tao ChenDepartment of Urology, Xiangyang Central Hospital, Xiangyang, China.
Xiaming PeiDepartment of Urology, Hunan Cancer Hospital, Changsha, China.
Guanghui GongDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Jiansheng TangDepartment of Urology, the Affiliated Hospital of Xiangnan University, Xiangnan University, Chenzhou, China.
Belaydi OthmaneDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Zhiyong CaiDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Chunyu ZhangDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Zhi LiuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Xiongbing ZuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. Electronic address: zuxbxy@csu.edu.cn.
Central South University · CNShanghai Jiao Tong University · CNCapital Medical University · CNChenzhou First People's Hospital · CNChina Medical University · CNHunan Cancer Hospital · CNHunan Normal University · CNSoochow University · CNSun Yat-sen University · CNXiangnan University · CNXiangyang Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To parallelly compare the efficacy of neoadjuvant immunotherapy (tislelizumab), neoadjuvant chemotherapy (gemcitabine and cisplatin), and neoadjuvant combination therapy (tislelizumab + GC) in patients with muscle-invasive bladder cancer (MIBC) and explore the efficacy predictors, we perform a multi-center, real-world cohort study that enrolls 253 patients treated with neoadjuvant treatments (combination therapy: 98, chemotherapy: 107, and immunotherapy: 48) from 15 tertiary hospitals. We demonstrate that neoadjuvant combination therapy achieves the highest complete response rate and pathological downstaging rate compared with neoadjuvant immunotherapy or chemotherapy. We develop and validate an efficacy prediction model consisting of pretreatment clinical characteristics, which can pinpoint candidates to receive neoadjuvant combination therapy. We also preliminarily reveal that patients who achieve pathological complete response after neoadjuvant treatments plus maximal transurethral resection of the bladder tumor may be safe to receive bladder preservation therapy. Overall, this study highlights the benefit of neoadjuvant combination therapy based on tislelizumab for MIBC.

Indexed as

Neoadjuvant TherapyUrinary Bladder NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCohort StudiesHumansImmunotherapyMusclesNeoplasm InvasivenessRetrospective Studies

Identifiers

PMID36265483
PMCPMC9729796
OpenAlexW4306797808

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.